Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01918371 · ClinicalTrials.gov registry record
A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 323
- Enrollment target
NCT01918371: Completed study, sponsored by Allergan.
NCT01918371 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 323 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01918371 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 323 participants
- Enrollment target
Study Summary
This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
Primary Outcome
BCVA was assessed using the Snellen eye chart converted to Early Treatment Diabetic Retinopathy Study number of lines ranging from 0 (worst) to 20 (best). 20/40 or better is equivalent to 14 or more lines read correctly. CRT was measured using OCT, a laser based non-invasive diagnostic system providing high-resolution imaging sections of the retina performed in the study eye after pupil dilation.
Interventions
- DRUG Anti-VEGF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2013-08-02 |
| Est. Completion | 2014-09-04 |
What the finished NCT01918371 record still lists
NCT01918371 is an observational study that tracks outcomes without assigning an intervention. The registered 323 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Anti-VEGF is the first listed.
NCT01918371 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01918371 about?
NCT01918371 is a clinical study titled "A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema". This retrospective data review study will evaluate anti-VEGF injections for retinal vein occlusion (RVO) or diabetic macular edema (DME).
What is the current status of trial NCT01918371?
This trial is currently completed. The enrollment target is 323 participants. The study started on 2013-08-02. Estimated completion is 2014-09-04.
What interventions are being tested in trial NCT01918371?
The interventions under investigation include: Anti-VEGF (DRUG).
Who is sponsoring clinical trial NCT01918371?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04164173 · 324 participants · NA
Hyperinflation Respiratory Therapies in Cardiac Surgery Patients
- NCT04708054 · 324 participants · Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- NCT05261399 · 324 participants · Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- NCT05353322 · 324 participants · NA
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI